首页> 美国卫生研究院文献>Journal of Cancer >Overexpression of SMOC2 Attenuates the Tumorigenicity of Hepatocellular Carcinoma Cells and Is Associated With a Positive Postoperative Prognosis in Human Hepatocellular Carcinoma
【2h】

Overexpression of SMOC2 Attenuates the Tumorigenicity of Hepatocellular Carcinoma Cells and Is Associated With a Positive Postoperative Prognosis in Human Hepatocellular Carcinoma

机译:SMOC2的过表达减弱肝细胞癌细胞的致瘤性并与人类肝细胞癌的积极术后预后相关

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Secreted modular calcium binding protein-2 (SMOC2), a recently identified matricellular protein that belongs to the SPARC protein family, has been reported to be downregulated in various cancers. The purpose of this study was to investigate the clinical significance and biological function of SMOC2 in human hepatocellular carcinoma. Real-time quantitative PCR and western blotting analyses revealed that SMOC2 mRNA and protein levels were significantly downregulated in human HCC tissues compared to the matched adjacent normal tissues. Clinicopathological analysis indicated that SMOC2 expression was significantly associated with tumor size, number of tumors, tumor-node-metastasis (TNM) stage and distant metastasis. Kaplan-Meier survival analysis showed that high tumor SMOC2 expression was associated with improved overall survival and disease-free survival in patients with HCC. Functional analyses (cell proliferation and colony formation assays, cell migration and invasion assays, cell cycle and apoptosis assays) demonstrated that stable overexpression of SMOC2 using a lentiviral vector significantly inhibited cell proliferation, colony formation, migration and invasion, and induced G0/G1 phase arrest in HCC cells in vitro. In addition, experiments with a mouse model revealed the suppressed effect of SMOC2 on HCC tumorigenicity and metastases in vivo. These results suggest that SMOC2 functions as a tumor suppressor during the development of HCC and may represent an effective prognostic factor and novel therapeutic target for HCC.
机译:分泌的模块化钙结合蛋白2(SMOC2)是最近发现的属于SPARC蛋白家族的基质细胞蛋白,据报道在多种癌症中均被下调。这项研究的目的是调查SMOC2在人类肝细胞癌中的临床意义和生物学功能。实时定量PCR和Western印迹分析显示,与匹配的相邻正常组织相比,人HCC组织中SMOC2 mRNA和蛋白水平显着下调。临床病理分析表明,SMOC2表达与肿瘤大小,肿瘤数量,肿瘤淋巴结转移(TNM)阶段和远处转移密切相关。 Kaplan-Meier生存分析表明,高肿瘤SMOC2表达与HCC患者改善的总体生存率和无病生存率有关。功能分析(细胞增殖和集落形成测定,细胞迁移和侵袭测定,细胞周期和凋亡测定)表明,使用慢病毒载体稳定表达SMOC2可显着抑制细胞增殖,集落形成,迁移和侵袭,并诱导G0 / G1期在体外捕获在HCC细胞中。此外,小鼠模型实验显示SMOC2对体内HCC致瘤性和转移的抑制作用。这些结果表明,SMOC2在肝癌的发展过程中起着抑癌作用,可能代表肝癌的有效预后因素和新的治疗靶点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号